• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Recombinant zoster vaccine reduced incidence of herpes zoster in autologous stem cell transplant recipients

byJason Nam, MDandDaniel Fisher
July 10, 2019
in Chronic Disease, Infectious Disease, Oncology
Reading Time: 2 mins read
5
Share on FacebookShare on Twitter

 1. In this randomized controlled trial, autologous hematopoietic stem cell transplantation patients who received 2 recombinant zoster vaccine doses had reduced incidence of herpes zoster compared to placebo.

2. Injection site pain, myalgia, and fatigue were the most common adverse reactions to the vaccine.

Evidence Rating Level: 1 (Excellent)

Study Rundown: After autologous hematopoietic stem cell transplantation (HSCT), there is risk of herpes zoster due to diminished T-cell immunity within the first 2 to 3 years. Vaccination can provide long-term protection against herpes zoster, but the vaccine cannot be live attenuated, as they are contraindicated in immunocompromised patients. In this randomized controlled trial, HSCT patients who received 2 doses of recombinant, non-live zoster vaccine shortly after autologous HSCT exhibited reduced incidence of herpes zoster after a median follow-up of close to 2 years compared to placebo. Injection site pain, myalgia, and fatigue were the most common adverse reactions to the vaccine.

While this represents a promising prophylactic treatment for these patients, this study has several limitations. There was not enough power to compare incidences of herpes zoster–related complications excluding post-herpetic neuralgia, post-herpetic neuralgia, and hospitalizations. Further, the study was not long enough to assess effects beyond the second year.

Click to read the study in JAMA

Relevant Reading: Herpes zoster after autologous haematopoietic stem cell transplantation without antiviral prophylaxis.

RELATED REPORTS

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

#VisualAbstract Underlying multiple myeloma remains the primary cause of death across all age groups of patients and across all lines of therapy

#VisualAbstract Post-transplant cyclophosphamide is associated with increased incidence of cytomegalovirus infection in hematopoietic cell transplant recipients

In-Depth [randomized controlled trial]: The Zoster Efficacy Study in Patients Undergoing HSCT (ZOE-HSCT) trial recruited 1846 patients who had undergone autologous HSCT. Patients were randomized to receive 2 doses of vaccine or placebo. The median follow-up of 21 months started 1 month after dose 2. 184 confirmed herpes zoster cases occurred in the modified total vaccinated cohort (49 vaccine recipients and 135 placebo recipients). The overall incidences of herpes zoster were 30 and 94 per 1000 person years in the vaccine and placebo groups, respectively, and the incidence rate ratio (IRR) of first herpes zoster episode was 0.32 (CI95 0.22-0.44). With regards to secondary outcomes, the number of participants with herpes zoster–related complications was low. Solicited injection site reactions and general symptoms occurring within 7 days of vaccination were more frequent in vaccine recipients (90%) than in placebo recipients (53%). Pain was the most common injection site symptom, occurring in 84% of vaccine recipients.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: herpes zosterrecombinant zoster vaccineshinglesstem cell transplant
Previous Post

#VisualAbstract: Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer

Next Post

Recombinant zoster vaccine reduced incidence of herpes zoster in autologous stem cell transplant recipients

RelatedReports

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia
StudyGraphics

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

June 12, 2022
#VisualAbstract Underlying multiple myeloma remains the primary cause of death across all age groups of patients and across all lines of therapy
StudyGraphics

#VisualAbstract Underlying multiple myeloma remains the primary cause of death across all age groups of patients and across all lines of therapy

August 6, 2021
#VisualAbstract Post-transplant cyclophosphamide is associated with increased incidence of cytomegalovirus infection in hematopoietic cell transplant recipients
StudyGraphics

#VisualAbstract Post-transplant cyclophosphamide is associated with increased incidence of cytomegalovirus infection in hematopoietic cell transplant recipients

June 25, 2021
#VisualAbstract Lenalidomide shows improvement in progression-free survival over bortezomib maintenance following autologous stem cell transplantation for multiple myeloma
StudyGraphics

#VisualAbstract Lenalidomide shows improvement in progression-free survival over bortezomib maintenance following autologous stem cell transplantation for multiple myeloma

January 28, 2021
Next Post
Decline in pediatric herpes zoster associated with varicella vaccine

Recombinant zoster vaccine reduced incidence of herpes zoster in autologous stem cell transplant recipients

Quick Take: Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent)

Quick Take: Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent)

Molecular testing for Clostridium difficile may not predict disease activity

Quick Take: Trends in diverting loop ileostomy vs. total abdominal colectomy as surgical management for Clostridium Difficile colitis

Please login to join discussion

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
  • Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma
  • Lebrikizumab effective in treating moderate-to-severe atopic dermatitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options